- Home
- Daily Diary
- Asset Class
- Sector
- Latest
- Author
- Street Notes
- TheStreet
- Switch to
- Premium Tools
- Real Money
- Real Money Pro
- Action Alerts PLUS
- Stocks Under $10
- Breakout Stocks
- Options Profits
Latest Commentary
Real Money: Independent market insight from a veteran team of trusted Wall Street pros.
• Up-to-the-minute reports on market activity
• Actionable trade ideas
• Up-to-the-minute reports on market activity
• Actionable trade ideas
Latest Strategies
Real Money Pro: Professional tools and specific trade ideas for active investors.
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
Latest Alert
May 17, 2013 | 06:41 PM EDT
We plan to continue building up our financial and technology positions over the coming weeks. FULL ALERT »
Action Alerts PLUS: Jim Cramer and Stephanie Link actively manage a real money portfolio for Jim's charitable trust.
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
Latest Alert
May 17, 2013 | 04:34 PM EDT
We used the strength this week to take some profits in three model portfolio positions, and we added to two other holdings. FULL ALERT »
Stocks Under $10: David Peltier manages a portfolio of affordable stocks with huge upside potential.
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
Latest Alert
May 17, 2013 | 10:07 AM EDT
There is some news on three of our model portfolio holdings. Here are the highlights. FULL ALERT »
Breakout Stocks: Bryan Ashenberg, CFA, manages a portfolio of small and mid-cap stocks with high growth potential.
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
Latest Commentary
Options Profits: Day in and day out, our team of professional options traders search for inventive plays for trading spikes in market activity, emerging trends, and breaking news and events. These veterans reveal all their charts and technical data — delivering daily strategies and insightful commentary written specifically for the options trader plus 40 options trade ideas per week!
Merck & Co Inc (MRK)
MRK (NYSE:Drugs)
$45.99
-0.38
-0.82%
Today's Range: 45.08 - 46.71 |
MRK Avg Daily Volume: 16,174,800
| Last Update: 05/17/13 - 4:00 PM EDT |
| Volume: 21,737,001 |
| YTD Performance: 12.34% |
| Open: $46.29 |
| Previous Close: $46.37 |
| 52 Week Range: $37.02 - $48.79 |
| Oustanding Shares: 3,019,611,844 |
| Market Cap: 140,019,401,206 |
Analysts Ratings
| Historical Rec | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago |
|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 10 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 4 | 4 | 4 | 5 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 |
| Mean Rec. | 1.75 | 1.75 | 1.75 | 1.83 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $0.83 | $0.92 | $3.49 | $3.78 |
| Number of Analysts | 6 | 6 | 9 | 10 |
| High Estimate | $0.87 | $0.95 | $3.56 | $4.00 |
| Low Estimate | $0.80 | $0.88 | $3.44 | $3.64 |
| Prior Year | $1.05 | $0.95 | $3.82 | $3.49 |
| Growth Rate (Year over Year) | -20.95% | -3.68% | -8.58% | 8.33% |
DDNotesMaker: Another DD sheet for $MRK was generated, check out http://t.co/287ePzlEur
1 hour ago from DDNotesMakerPost
1 hour ago from DDNotesMakerPost
KeelePharmSci: RT @FiercePharma: Check out our Top 10 #cardio drugs of 2012, including #Lipitor, #Diovan and #Zetia. http://t.co/tDu8ksXsv7 $NVS $PFE $MRK #pharma
7 hours ago from Twitter for Android
7 hours ago from Twitter for Android
buypropeciaonli: More #PROPECIA horror stories: tco/nIbENdNuVU #FDA $MRK Buy Propecia Here > tco/4TsZHEbPIl Buy Propecia Here > http://t.co/4TsZHEbPIl
12 hours ago from dlvr.it
12 hours ago from dlvr.it
buypropeciaonli: More #PROPECIA horror stories: tco/nIbENdNuVU #FDA $MRK Buy Propecia Here > http://t.co/4TsZHEbPIl
13 hours ago from dlvr.it
13 hours ago from dlvr.it
RecallPropecia: More #PROPECIA horror stories: http://t.co/nIbENdNuVU #FDA $MRK
13 hours ago from web
13 hours ago from web
SeekingAlpha: Oncothyreon A Speculative Buy http://t.co/QTSNrTADch $BMY $MKGAY.PK $MRK $ONTY
14 hours ago from Seeking Alpha
14 hours ago from Seeking Alpha
idirections: Commented on: "Bristol-Myers, Merck And Roche: R&D Finds Golden Pill, So Buy" http://t.co/SPaCHYjtyV $BMY $MRK $RHHBF.PK $IHF
15 hours ago from SeekingAlpha.com
15 hours ago from SeekingAlpha.com
LCDCorpBonds: Shareholders benefit as HG bond issuance volume surges in 2Q $ http://t.co/BDAUvSYFSC $AAPL $MRK $HD $RF
17 hours ago from HootSuite
17 hours ago from HootSuite
Here are seven reasons why.
You can't get away from the need for good yield in an era of commodity inflation.
TheStreet Sr. Columnst Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.
Many of these firms are pouring money into share buybacks -- instead of their long-term pipelines.
Focusing on near-term drug stock earnings is the wrong move.
Showing signs of technical deterioration.
When Europe's tame and China's out of the news, they come back to our stocks.
TheStreet's Jim Cramer says Abbott Labs will benefit from growth in emerging markets and Glaxo will benefit from a "huge pipeline of approvals." The Action Alerts Plus portfolio recently bought Glaxo shares and added to their position in Abbott Labs.
Jim Cramer looks at why he is highlighting pharma along with growth biotech, with Nicole Urken, Mad Money Research Associate.
How much to buy?
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
© 2013 TheStreet, Inc. All rights reserved.